New guidelines on migraine prevention reflect increasing options for patients Since 2012, the FDA has approved a half dozen new medications By Isabella CuetoAug. 31, 2026 Chronic Disease Reporter

https://www.statnews.com/2026/08/31/migraine-prevention-medication-guidelines/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-_138aT13bjrzopKXIlbkM30g3rgHkB6i8ewiBQfvOB5U9t-5jaxxSOgtGICE_HhvKxCsrDypD_P7nG7nGe-mCXlMuF9g&_hsmi=436432001&utm_content=436432001&utm_source=hs_email New migraine guidelines highlight growing treatment options The American Headache Society and the American Academy of Neurology released new migraine guidelines yesterday, the first time they've done so since 2012. The groups gave high marks on efficacy and tolerability to AbbVie's Qulipta, Lundbeck's Vyepti, Amgen and Novartis' Aimovig, Teva's Ajovy, and Lilly's Emgality. They also recommended the drugs as a preventive option for patients who frequently rely on pain medication once their attacks begin. Some experts, however, were concerned that the new guidelines are complicated and may scare off primary care doctors.

Can buying a drug patent application be seen as a bid to prolong a monopoly? Amgen and an insurer are battling over the answer, and the FTC has weighed in

https://www.statnews.com/pharmalot/2026/08/31/pending-drug-patent-applications-amgen-carefirst/ By Ed SilvermanAug. 31, 2026 Pharmalot Columnist, Senior Writer

The Trump administration is burying science and health care in paperwork Despite a stated focus on ‘finding efficiencies,’ the White House has increased the bureaucracy scientists, Medicaid beneficiaries must navigate

https://www.statnews.com/2026/09/01/white-house-science-medicaid-bureaucracy-paperwork/ By Abdullah Shihipar and Brandon D.L. MarshallSept. 1, 2026 Shihipar directs narrative projects and policy impact initiatives at the People, Place, and Health Collective at the Brown University School of Public Health. Marshall is a professor of epidemiology at the Brown University School of Public Health, and director of the People, Place, and Health Collective.

Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more President Trump has announced the next round of pricing deals with drugmakers

https://www.statnews.com/pharmalot/2026/09/01/novartis-bristol-trials-paused-pancreatic-cancer-drug-price-pharmalittle-newsletter/ By Andrew JosephSept. 1, 2026 Europe Correspondent

NIH proposal to cap research grants draws mixed reception, agency says Many of the 3,300 commenters stress need to support early career scientists By Anil OzaSept. 1, 2026 General Assignment Reporter

https://www.statnews.com/2026/09/01/nih-grant-cap-proposal-researcher-feedback/

As MAHA champions nutrition, it’s ignoring the experts, dietitians say Highly trained nutrition workforce faces drooping enrollment, low pay, and new barriers By Lauren Chan and Isabella CuetoSept. 1, 2026

https://www.statnews.com/2026/09/01/maha-nutrition-makeover-hampered-dietitian-workforce-crisis/

5 burning questions on Trump’s latest deals with drugmakers Agreements leave open questions for patients, companies, and policymakers alike By Daniel Payne, Elaine Chen, and John WilkersonSept. 1, 2026

https://www.statnews.com/2026/09/01/trump-pharma-deals-analysis-latest-round-most-favored-nation-drug-pricing/